Reata Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in CTD-PAH Patients and Reports Positive Interim Data From CTD-PAH Patients in Phase 2 LARIAT Trial
- First Patient Has Been Enrolled In Phase 3 CATALYST Trial In CTD-PAH
- Updated Data from CTD-PAH Patients in Phase 2 LARIAT Trial Demonstrate Improvements Consistent with the Previously Reported Cohort 1 Data
- Design, Size, and Statistical Power of CATALYST are Adequate to Detect the Treatment Effect Observed in the Phase 2 LARIAT Trial
- Data from CATALYST are expected to be available in H1 2018
IRVING, Texas, Oct. 06, 2016
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or “the Company”) today announced that it has enrolled the first patient into its Phase 3 trial (CATALYST) to evaluate the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).
Read the full news release from Reata Pharmaceuticals.